DING
2.9.2021 13:02:11 CEST | Business Wire | Press release
Ding , the world’s largest mobile top-up service, is pleased to announce that it has agreed to sell a majority stake to Pollen Street Capital Private Equity (“Pollen Street”). Pollen Street Capital, a London-based, independent, alternative investment management company, will take a majority stake in the company, in partnership with a substantial investment from the existing founder Mark Roden. The transaction is expected to complete in September.
Commenting on the announcement, Mark Roden, Founder and Chief Executive of Ding said: “We are delighted to announce the investment by Pollen Street Capital. The addition of a strategic investor to our company marks an important milestone for Ding and sets us up for significant growth. Sixteen years ago, we set out with a mission to solve a real problem, to simplify how people separated from their loved ones could stay connected to those back home. At that time, the process was cumbersome and inefficient and today through Ding’s platform we have transformed how people stay connected. We are proud that we are now the global leader and have earned the trust of millions of customers all over the world.”
Founded in 2006 by Mark Roden, Ding is the global leader in international top-up and credit transfers, offering customers the ability to top-up online, on the Ding app, via partners through the Ding API and in over 600,000 retail stores all over the world. Ding now serves millions of customers around the world – who have sent almost a half a billion tops-ups since we began. Pollen Street’s investment will support Ding to continue its strong growth trajectory, expand its technology platform, develop new products and expand into new geographies which will help the Company grow its global customer base and to build out the critical social purpose of keeping communities and families connected.
He added: “Over the years we have explored different investment partners and opportunities but we ultimately chose Pollen Street Capital due to their understanding of our vision for the business, but also due to their extensive and deep expertise in impact investing. We continue to be a socially driven company and we felt that in Pollen Street we had a partner that shared our values.”
He continued: “I would like to thank all our employees past and present who have helped build Ding to become the market leader. With 6 billion prepaid phones in the world and an ever-increasing demand for mobile data there is a significant market opportunity to offer more products and services to current and future customers.”
Ian Gascoigne, Partner at Pollen Street, said: “We are delighted to welcome Mark and his team to the Pollen Street portfolio. Ding has demonstrated an impressive track record and we look forward to partnering with the team to accelerate this growth and maximising the potential of Ding’s multi-channel top-up ecosystem during our investment period. Ding exemplifies Pollen Street’s investment strategy of identifying market leading technology businesses, whose propositions can be enhanced through further investment into technology and an increasing use of data. Ding also represents our commitment to Invest With Impact. As a global platform that connects friends, family, and dispersed communities across the world, Ding allows its customers to send mobile credit and data through a simple, safe, and convenient top-up service. In doing so, Ding fosters closer links and community ties between its users whilst promoting financial inclusion and global connectivity through its highly accessible and easy to use platform.”
Ding was advised by Jefferies, Davis Polk, A&L Goodbody, KPMG and PWC. Pollen Street was advised by Keefe, Bruyette & Woods (a Stifel Company), McCann FitzGerald, Buckley and Deloitte.
Financial terms of the deal were not disclosed.
***ENDS***
About: Ding.com
About: Pollen Street Capital
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom